Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Elektrofi | 2024 | Series C | $112.3M | Boston |
| Halda Therapeutics | 2024 | Series B | $126.0M | New Haven |
| Idrx | 2024 | Series B | $120.0M | Cambridge |
| MBX Biosciences | 2024 | Series C | $63.5M | Carmel |
| Outpace Bio | 2024 | Series B | $144.0M | Seattle |
| Bright Peak Therapeutics | 2024 | Series C | $90.0M | Allschwil |
| Interius BioTherapeutics | 2024 | Series B | $51.4M | Philadelphia |
| Ajax Therapeutics | 2024 | Series C | $95.0M | Cambridge |
| Bluejay Therapeutics | 2024 | Series C | $182.0M | San Mateo |
| Asher Bio | 2024 | Series C | $55.0M | San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 151 | Elektrofi | Series C | $112.3M | Boston, United States |
| 152 | Halda Therapeutics | Series B | $126.0M | New Haven, United States |
| 153 | Idrx | Series B | $120.0M | Cambridge, United States |
| 154 | MBX Biosciences | Series C | $63.5M | Carmel, United States |
| 155 | Outpace Bio | Series B | $144.0M | Seattle, United States |
| 156 | Bright Peak Therapeutics | Series C | $90.0M | Allschwil, Switzerland |
| 157 | Interius BioTherapeutics | Series B | $51.4M | Philadelphia, United States |
| 158 | Ajax Therapeutics | Series C | $95.0M | Cambridge, United States |
| 159 | Bluejay Therapeutics | Series C | $182.0M | San Mateo, United States |
| 160 | Asher Bio | Series C | $55.0M | San Francisco, United States |
Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.
Halda Therapeutics is a research-stage drug discovery company.
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Asher Bio is a biotechnology company that specializes in the fields of therapeutics builds better immunotherapy for cancer.
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.
Mariana Oncology is a biotechnology research industry.
ExcepGen is solving fundamental underlying problems in drug discovery to create a new generation of therapeutics.
Capacity Bio is a therapeutics company that is focused on mitophagy.
Cooks Venture operates as a regenerative pasture-raised chicken and meat company.
Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.
Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.
Phathom Pharmaceuticals is a biopharmaceutical company.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
RA Capital Management has invested in 439 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 19 different industry categories.
Among tracked funding rounds, Verdiva Bio received $411.0M in a Series A round. RA Capital Management's total known invested capital is $40.6B.
RA Capital Management's average investment size is $110.2M across its portfolio of 439 companies.
Recent RA Capital Management portfolio additions include Elektrofi, Halda Therapeutics, Idrx, MBX Biosciences, Outpace Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors